Compare IDEXX Laboratories, Inc. (IDXX) vs Virgin Galactic Holdings, Inc. (SPCE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Virgin Galactic Holdings, Inc. — how do they compare? IDEXX Laboratories, Inc. trades at $519.54 (market cap $40.43B), while Virgin Galactic Holdings, Inc. trades at $2.87 (market cap $445.69M). The key difference: IDEXX Laboratories, Inc. is far larger — about 90.7× Virgin Galactic Holdings, Inc.'s market cap, and IDEXX Laboratories, Inc. is more actively traded (692,164 versus 5,128,850). Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and Virgin Galactic Holdings, Inc. for 69 Days on average.
| IDXX | SPCE | |
|---|---|---|
Market Cap | $40.43B | $445.69M |
Volume | 692,164 | 5,128,850 |
Sector | Health | Industrials |
52-Week High | $766.68 | $7.52 |
52-Week Low | $504.70 | $2.17 |
Typical Hold Time | 46 Days | 69 Days |
Enterprise Value | $41.32B | $409.68M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $519.87, up 2.61% on the day, with a bearish technical signal from moving averages but strong fundamentals including a 25.03% net income margin and consistent earnings beats. Revenue grew to $4.3B in 2025, and the company recently acquired CoVetAI to enhance veterinary workflow intelligence, signaling strategic expansion.
The stock's outlook is supported by robust profitability and analyst consensus, but faces headwinds from technical weakness and potential market volatility. With a $665 price target implying significant upside, the primary risks include competitive pressures and execution of growth initiatives amid economic uncertainties.
SPCE trades at $2.875, down 4.49% on the day, reflecting ongoing volatility amid negative profitability and cash burn. The company continues to post significant losses, with a net income margin of -23,867.44% in 2025, though recent quarters have shown smaller-than-expected EPS losses. Technical indicators are bearish, with moving averages signaling selling pressure, while RSI levels suggest potential oversold conditions. Recent news highlights a delay in commercial Delta flights to 2027 but strong ticket demand and a legal settlement resolution.
The outlook remains high-risk due to persistent cash outflows and delayed revenue growth, yet long-term potential in space tourism offers speculative upside. Investment hinges on successful execution of the 2027 cash flow target and commercial flight timeline, but shareholder dilution and high short interest pose substantial risks. Analyst consensus is mixed, with 29% buy ratings reflecting cautious optimism amid fundamental challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Virgin Galactic Holdings, Inc.
Virgin Galactic Holdings Inc. develops space vehicles. The Company designs exploration technology such as missiles, rockets, and other related equipment. Virgin Galactic Holdings serves customers in the United States.
Read more on SPCE →
